Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2025 | $18.00 → $24.00 | Neutral → Buy | H.C. Wainwright |
| 10/21/2024 | $20.00 | Neutral | H.C. Wainwright |
| 10/8/2024 | $29.00 | Overweight | Wells Fargo |
| 11/18/2022 | $33.00 | Neutral | BofA Securities |
| 10/11/2022 | $40.00 | Overweight | Morgan Stanley |
| 11/19/2021 | $42.00 → $53.00 | Buy | Citigroup |
| 11/19/2021 | $48.00 → $60.00 | Overweight | Barclays |
| 11/18/2021 | $68.00 → $100.00 | Outperform | SVB Leerink |
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 8,400 shares of the Company's common stock at an exercise price per share of $9.85, which was the closing price on June 9, 2025, and restricted stock units to acquire a total of 4,200 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 p
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly Arcus will host a conference call to discuss these data at 5:0
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 13,400 shares of the Company's common stock at an exercise price per share of $9.02, which was the closing price on May 23, 2025, and restricted stock units to acquire a total of 13,400 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 20
H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously
H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00
Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
SCHEDULE 13G - Arcus Biosciences, Inc. (0001724521) (Subject)